Clinical evaluation of commercial automated SARS-CoV-2 immunoassays
Objective - Numerous immunoassays for detecting antibodies directed against SARS-CoV-2 have been rapidly developed and released. Validations of these have been performed with a limited number of samples. The lack of standardisation might lead to significantly different results. This study compared t...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
February 2021
|
| In: |
International journal of infectious diseases
Year: 2021, Jahrgang: 103, Pages: 590-596 |
| ISSN: | 1878-3511 |
| DOI: | 10.1016/j.ijid.2020.12.003 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ijid.2020.12.003 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1201971220325261 
|
| Verfasserangaben: | Maximilian Kittel, Maria Christina Muth, Ingrid Zahn, Heinz-Jürgen Roth, Margot Thiaucourt, Catharina Gerhards, Verena Haselmann, Michael Neumaier, Peter Findeisen |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1752963865 | ||
| 003 | DE-627 | ||
| 005 | 20230427070845.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210331s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2020.12.003 |2 doi | |
| 035 | |a (DE-627)1752963865 | ||
| 035 | |a (DE-599)KXP1752963865 | ||
| 035 | |a (OCoLC)1341403045 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kittel, Maximilian |d 1987- |e VerfasserIn |0 (DE-588)1156691699 |0 (DE-627)1019529741 |0 (DE-576)502380136 |4 aut | |
| 245 | 1 | 0 | |a Clinical evaluation of commercial automated SARS-CoV-2 immunoassays |c Maximilian Kittel, Maria Christina Muth, Ingrid Zahn, Heinz-Jürgen Roth, Margot Thiaucourt, Catharina Gerhards, Verena Haselmann, Michael Neumaier, Peter Findeisen |
| 264 | 1 | |c February 2021 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 31.03.2021 | ||
| 520 | |a Objective - Numerous immunoassays for detecting antibodies directed against SARS-CoV-2 have been rapidly developed and released. Validations of these have been performed with a limited number of samples. The lack of standardisation might lead to significantly different results. This study compared ten automated assays from six vendors in terms of sensitivity, specificity and reproducibility. - Methods - This study compared ten fully automated immunoassays from the following vendors: Diasorin, Epitope Diagnostics, Euroimmun, Roche, YHLO, and Snibe. The retrospective part of the study included patients with a laboratory-confirmed COVID-19 infection, and controls comprised patients with a suspected infection, in whom the disease was excluded. Furthermore, biobanked sera were taken as negative controls (n = 97). The retrospective part involved four groups: (1) laboratory-confirmed COVID-19 infection (n = 183); (1B) suspected COVID-19 infection (n = 167) without a qRT-PCR result but positive serological results from at least two different assays, and suspected COVID-19 infection due to a positive serological result from the Roche assay (n = 295); (2) biobanked sera obtained from patients before the emergence of SARS-CoV-2 (n = 97) as negative controls; and (2A) probably COVID-19-negative sera with negative serological results from at least two different assays (n = 152). - Results - Overall diagnostic sensitivities were: Euroimmun (IgA) 87%; Epitope Diagnostics (IgG) 83%; YHLO (IgG) 77%; Roche (IgM/IgG) 77%; Euroimmun (IgG) 75%; Diasorin (IgG) 53%; Epitope Diagnostics (IgM) 52%; Snibe (IgG) 47%; YHLO (IgM) 35%; and Snibe (IgM) 26%. Diagnostic specificities were: YHLO (IgG) 100%; Roche, 100%; Snibe (IgM/IgG) 100%; Diasorin (IgG) 97%; Euroimmun (IgG) 94%; YHLO (IgM) 94%; Euroimmun (IgA) 83%. - Conclusion - Assays from different vendors substantially varied in terms of their performance. These findings might facilitate selection of appropriate serological assays. | ||
| 650 | 4 | |a Automated SARS-CoV-2 antibody detection | |
| 650 | 4 | |a High throughpu testing | |
| 650 | 4 | |a Longitudional monitoring of antibody development | |
| 650 | 4 | |a Pandemic control | |
| 650 | 4 | |a Seroconversion | |
| 650 | 4 | |a Serpprevalence | |
| 700 | 1 | |a Thiaucourt, Margot |d 1993- |e VerfasserIn |0 (DE-588)1156311373 |0 (DE-627)1018863850 |4 aut | |
| 700 | 1 | |a Gerhards, Catharina |d 1992- |e VerfasserIn |0 (DE-588)1226262503 |0 (DE-627)1747234710 |4 aut | |
| 700 | 1 | |a Haselmann, Verena |d 1982- |e VerfasserIn |0 (DE-588)1153803097 |0 (DE-627)1015321275 |0 (DE-576)500568154 |4 aut | |
| 700 | 1 | |a Neumaier, Michael |d 1958- |e VerfasserIn |0 (DE-588)1028284934 |0 (DE-627)730532623 |0 (DE-576)375780580 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of infectious diseases |d Amsterdam [u.a.] : Elsevier, 1997 |g 103(2021), Seite 590-596 |h Online-Ressource |w (DE-627)341907669 |w (DE-600)2070533-5 |w (DE-576)271360844 |x 1878-3511 |7 nnas |a Clinical evaluation of commercial automated SARS-CoV-2 immunoassays |
| 773 | 1 | 8 | |g volume:103 |g year:2021 |g pages:590-596 |g extent:7 |a Clinical evaluation of commercial automated SARS-CoV-2 immunoassays |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ijid.2020.12.003 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S1201971220325261 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210331 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 1028284934 |a Neumaier, Michael |m 1028284934:Neumaier, Michael |d 60000 |d 63300 |e 60000PN1028284934 |e 63300PN1028284934 |k 0/60000/ |k 1/60000/63300/ |p 8 | ||
| 998 | |g 1153803097 |a Haselmann, Verena |m 1153803097:Haselmann, Verena |d 60000 |e 60000PH1153803097 |k 0/60000/ |p 7 | ||
| 998 | |g 1226262503 |a Gerhards, Catharina |m 1226262503:Gerhards, Catharina |d 60000 |d 63300 |e 60000PG1226262503 |e 63300PG1226262503 |k 0/60000/ |k 1/60000/63300/ |p 6 | ||
| 998 | |g 1156311373 |a Thiaucourt, Margot |m 1156311373:Thiaucourt, Margot |d 60000 |d 63300 |e 60000PT1156311373 |e 63300PT1156311373 |k 0/60000/ |k 1/60000/63300/ |p 5 | ||
| 998 | |g 1156691699 |a Kittel, Maximilian |m 1156691699:Kittel, Maximilian |d 60000 |d 63300 |e 60000PK1156691699 |e 63300PK1156691699 |k 0/60000/ |k 1/60000/63300/ |p 1 |x j | ||
| 999 | |a KXP-PPN1752963865 |e 389952599X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"physDesc":[{"extent":"7 S."}],"name":{"displayForm":["Maximilian Kittel, Maria Christina Muth, Ingrid Zahn, Heinz-Jürgen Roth, Margot Thiaucourt, Catharina Gerhards, Verena Haselmann, Michael Neumaier, Peter Findeisen"]},"relHost":[{"id":{"eki":["341907669"],"issn":["1878-3511"],"zdb":["2070533-5"]},"recId":"341907669","language":["eng"],"titleAlt":[{"title":"IJID"}],"disp":"Clinical evaluation of commercial automated SARS-CoV-2 immunoassaysInternational journal of infectious diseases","physDesc":[{"extent":"Online-Ressource"}],"part":{"extent":"7","volume":"103","pages":"590-596","text":"103(2021), Seite 590-596","year":"2021"},"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"dateIssuedKey":"1997","dateIssuedDisp":"1997-","publisher":"Elsevier ; Decker","publisherPlace":"Amsterdam [u.a.] ; Hamilton, Ont."}],"title":[{"title":"International journal of infectious diseases","title_sort":"International journal of infectious diseases"}],"pubHistory":["1.1996/97 -"],"note":["Gesehen am 29.01.25","Fortsetzung der Druck-Ausgabe"]}],"recId":"1752963865","id":{"eki":["1752963865"],"doi":["10.1016/j.ijid.2020.12.003"]},"note":["Gesehen am 31.03.2021"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedDisp":"February 2021","dateIssuedKey":"2021"}],"person":[{"role":"aut","display":"Kittel, Maximilian","given":"Maximilian","family":"Kittel"},{"given":"Margot","family":"Thiaucourt","display":"Thiaucourt, Margot","role":"aut"},{"role":"aut","display":"Gerhards, Catharina","family":"Gerhards","given":"Catharina"},{"display":"Haselmann, Verena","family":"Haselmann","given":"Verena","role":"aut"},{"display":"Neumaier, Michael","family":"Neumaier","given":"Michael","role":"aut"}],"title":[{"title_sort":"Clinical evaluation of commercial automated SARS-CoV-2 immunoassays","title":"Clinical evaluation of commercial automated SARS-CoV-2 immunoassays"}]} | ||
| SRT | |a KITTELMAXICLINICALEV2021 | ||